Key Market Indicator:
F&G: 23
25.437,00 NASDAQ · 47.695,00 DOW · 6.818,20 S&P · 4.222,77 Gold · 62,24 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
© ACCESSWIRE
25.06.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations' CEO to Host Special Investors' Conference Call on Wednesday, July 2, 2025
News Preview
VANCOUVER, BC / ACCESS Newswire / June 25, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H), (WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that Mr. Thomas O'Shaughnessy, Onco-Innovations' CEO, will host a special investors' conference call, on Wednesday, July 2, 2025 at 2:00 p.m. PST/5:0...
Themefolio
Profiler
Peergroup
© EQS Newswire
21.06.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Erhebliche Aufwärtsperspektive für frühe Investoren? Neue Studie unterstützt die Anwendbarkeit der Ergebnisse klinischer Lungenkrebsstudien 
News Preview
EQS-Media / 21.06.2025 / 15:37 CET/CEST Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass die Mitbegründer seiner hundertprozentigen Tochtergesellschaft Inka Health Corp. eine wichtige neue Studie mit dem Titel “Global Transportability of Clinical Trial Outcomes to Real-World......
Themefolio
Profiler
Peergroup
© EQS Newswire
21.06.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Mitbegründer von Inka Health veröffentlichen neue Studie, die die Anwendbarkeit der Ergebnisse klinischer Lungenkrebsstudien in der realen Welt unterstützt
News Preview
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ) (Onco oder das Unternehmen) freut sich bekannt zu geben, dass die Mitbegründer seiner hundertprozentigen Tochtergesellschaft Inka Health Corp. (Inka Health) eine wichtige neue Studie mit dem Titel Global Transportability of Clinical Trial Outcomes to Real-World Lung Cancer Populations: A Case......
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar

USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© ACCESSWIRE
20.06.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Inka Health Co-Founders Publish New Study Advancing Real-World Applicability of Lung Cancer Clinical Trial Outcomes
News Preview
VANCOUVER, BC / ACCESS Newswire / June 20, 2025 / Onco-Innovations Limited(CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that the Co-Founders of its wholly-owned subsidiary, Inka Health Corp. ("Inka Health"), have authored a significant new study titled Global Tra...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© EQS Newswire
14.06.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Ein intelligenter Pick für visionäre Anleger? Onco-Innovations beauftragt die University of Alberta und das Cross Cancer Institute mit präklinischer Studie
News Preview
EQS-Media / 14.06.2025 / 17:58 CET/CEST Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass es eine Vereinbarung mit der University of Alberta und dem Cross Cancer Institute zur Durchführung einer präklinischen Studie getroffen hat, die die Absicht des Unternehmens unterstützt,......
Themefolio
Profiler
Peergroup
© EQS Newswire
14.06.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations beauftragt die University of Alberta und das Cross Cancer Institute mit der Ausweitung der PNKP-Inhibitor-Forschung auf schwer zu behandelnde Krebsarten
News Preview
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass es eine Vereinbarung mit der University of Alberta und dem Cross Cancer Institute zur Durchführung einer präklinischen Studie getroffen hat, die die Absicht des Unternehmens unterstützt, den Forschungsumfang seiner Nanopartikel-For......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
13.06.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations Engages the University of Alberta and Cross Cancer Institute to Expand PNKP Inhibitor Research into Hard-to-Treat Cancers
News Preview
VANCOUVER, BC / ACCESS Newswire / June 13, 2025 / Onco-Innovations Limited (CBOE:ONCO)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has entered into an agreement with the University of Alberta and Cross Cancer Institute to undertake a preclinical study that supports the Company's intention...
Themefolio
Profiler
Peergroup
© EQS Newswire
06.06.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations-Tochter Inka Health gründet globales KI-Onkologie-Konsortium
News Preview
EQS-Media / 06.06.2025 / 11:20 CET/CEST Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), „Onco“ oder das „Unternehmen“) gibt bekannt, dass seine hundertprozentige Tochtergesellschaft Inka Health Corp. eine neue strategische Initiative zur Gründung eines globalen Konsortiums startet, das den Einsatz künstlicher Intelligenz (KI) in der ......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.06.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Inka Health von Onco-Innovations startet globales KI-Onkologie-Konsortium zur Förderung der prädiktiven Krebsforschung
News Preview
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass seine hundertprozentige Tochtergesellschaft Inka Health Corp. (Inka Health) eine neue strategische Initiative zur Gründung eines globalen Konsortiums zur Förderung der Nutzung künstlicher Intelligenz (KI) in der Onkologie startet. ......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
05.06.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations' Inka Health to Launch Global AI-Oncology Consortium to Advance Predictive Cancer Research
News Preview
VANCOUVER, BC / ACCESS Newswire / June 5, 2025 / Onco-Innovations Limited (CBOE:ONCO)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly-owned subsidiary, Inka Health Corp. ("Inka Health"), is launching a new strategic initiative to establish a global consortium dedicated to adv...
Themefolio
Profiler
Peergroup
© EQS Newswire
27.05.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations leitet nächste Phase der Krebstherapie-Entwicklung ein
News Preview
EQS-Media / 27.05.2025 / 11:58 CET/CEST Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekanntzugeben, dass Dalton Pharma Services die Produktion zur Herstellung von Material für die präklinische Prüfung der exklusiv lizenzierten Polynukleotidkinase-3'-Phosphatase (PNKP)-Inhibitortechnologie des......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.05.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations gibt den Beginn der Herstellung von präklinischem Testmaterial für seine PNKP-Inhibitortechnologie durch Dalton Pharma bekannt
News Preview
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekanntzugeben, dass Dalton Pharma Services (Dalton) die Produktion zur Herstellung von Material für die präklinische Prüfung der exklusiv lizenzierten Polynukleotidkinase-3'-Phosphatase (PNKP)-Inhibitortechnologie des Unternehmens aufgenommen hat. Diese......
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© ACCESSWIRE
26.05.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations Announces Start of Manufacturing of Preclinical Testing Material for Its PNKP Inhibitor Technology by Dalton Pharma
News Preview
VANCOUVER, BC / ACCESS Newswire / May 26, 2025 / Onco-Innovations Limited (CBOE:ONCO) (Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that Dalton Pharma Services ("Dalton") has commenced activities to manufacture material for preclinical testing of the Company's exclusively-licensed nanopar...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
26.05.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations Extends Marketing Program
News Preview
VANCOUVER, BC / ACCESS Newswire / May 26, 2025 / Onco-Innovations Limited (CBOE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H)(WKN:A3EKSZ) ("Onco" or the "Company") announces, further to its news release dated March 25, 2025, that it has extended the term of its engagement with MCS Market Communication Service GmbH (business address: Rheinpr...
Themefolio
Profiler
Peergroup
© EQS Newswire
23.05.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Renommierter Prof. Steven Jones zum Senior Scientific Advisor ernannt
News Preview
EQS-Media / 23.05.2025 / 11:10 CET/CEST Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, gibt die Ernennung von Professor Steven Jones zum Senior Scientific Advisor bekannt. Professor Jones wird eine Schlüsselrolle bei der Verwirklichung der Mission des Unternehmens spielen, die Krebsbehandlung durch KI-gest......
Themefolio
Profiler
Peergroup
© EQS Newswire
23.05.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations gibt Ernennung von Professor Steven Jones zum Senior Scientific Advisor bekannt und stärkt damit seine technische Kompetenz im Bereich der KI-gestützten Präzisionsonkologie
News Preview
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, gibt die Ernennung von Professor Steven Jones zum Senior Scientific Advisor bekannt. Professor Jones wird eine Schlüsselrolle bei der Verwirklichung der Mission des Unternehmens spielen, die Krebsbehandlung durch KI-gestützte Präzisionsonkologie zu revolutionieren.......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
22.05.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations Announces Appointment of Professor Steven Jones as Senior Scientific Advisor, Strengthening Technical Acumen in AI-Powered Precision Oncology
News Preview
VANCOUVER, BC / ACCESS Newswire / May 22, 2025 / Onco-Innovations Limited (CBOE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce the appointment of Professor Steven Jones as Senior Scientific Advisor. Professor Jones will play a key role in advancing the Company's mission to transfor...
Themefolio
Profiler
Peergroup
© BusinessWire
22.05.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations Uplists to Cboe Canada
News Preview
Cboe Canada Inc. (“Cboe Canada”) is pleased to announce that Onco-Innovations Limited (“Onco”), a Canadian-based company dedicated to cancer research and treatment, has uplisted to Cboe Canada and is available for trading under the ticker symbol ONCO. Onco has a core mission to prevent and cure cancer through cutting edge science. The company hol...
Themefolio
Profiler
Peergroup
© Newsfile
20.05.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
CSE Bulletin: Delist - Onco-Innovations Limited (ONCO)
News Preview
Toronto, Ontario--(Newsfile Corp. - Le 20 mai/May 2025) - The common shares of Onco-Innovations Limited will be delisted from the CSE at market close, May 21, 2025. Onco-Innovations Limited will continue to trade on Cboe. _________________________________ Les actions ordinaires d'Onco-Innovations Limited ser...
Themefolio
Profiler
Peergroup
© EQS Newswire
17.05.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations erobert CBOE Canada 
News Preview
EQS-Media / 17.05.2025 / 12:10 CET/CEST Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass es die Notierung seiner Stammaktien von der Canadian Securities Exchange (CSE) an die Cboe Canada Inc. übertragen wird. Onco geht davon aus, dass seine Stammaktien ab dem 22. Mai 2025 un......
Themefolio
Profiler
Peergroup
© EQS Newswire
17.05.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations feiert die Notierung seiner Stammaktien an der CBOE Canada
News Preview
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass es die Notierung seiner Stammaktien (Stammaktien) von der Canadian Securities Exchange (CSE) an die Cboe Canada Inc. (Cboe Canada) übertragen wird. Onco geht davon aus, dass seine Stammaktien ab dem 22. Mai 2025 unter dem bestehend......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
16.05.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations Celebrates Listing of Common Shares on Cboe Canada
News Preview
VANCOUVER, BC / ACCESS Newswire / May 16, 2025 / Onco-Innovations Limited (CSE:ONCO) ("Onco" or the "Company") is pleased to announce that it will transfer the listing of its common shares (the "Common Shares") to Cboe Canada Inc. ("Cboe Canada") from the Canadian Securities Exchange ("CSE"). Onco e...
Themefolio
Profiler
Peergroup
© EQS Newswire
25.04.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
AstraZeneca Canada und Onco-Innovations-Tochter Inka Health vertiefen analytische Zusammenarbeit im Kampf gegen Krebs
News Preview
EQS-Media / 25.04.2025 / 10:56 CET/CEST Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekanntzugeben, dass seine hundertprozentige Tochtergesellschaft Inka Health Corp., am 20. März 2025 eine neue Vereinbarung über analytische Arbeiten mit AstraZeneca Canada unterzeichnet hat. Die Dienstleistun......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.04.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Inka Health von Onco-Innovations unterzeichnet eine neue analytische Zusammenarbeit mit AstraZeneca Canada, um reale Evidenz in der Regulierungswissenschaft zu fördern
News Preview
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekanntzugeben, dass seine hundertprozentige Tochtergesellschaft Inka Health Corp. (Inka Health), am 20. März 2025 eine neue Vereinbarung über analytische Arbeiten mit AstraZeneca Canada (AstraZeneca) unterzeichnet hat. Die Dienstleistungen im Rahmen die......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
24.04.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations' Inka Health Signs New Analytical Work with AstraZeneca Canada to Advance Real-World Evidence in Regulatory Science
News Preview
VANCOUVER, BC / ACCESS Newswire / April 24, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly owned subsidiary, Inka Health Corp. ("Inka Health"), signed a new analytical work contract[1] with AstraZeneca Canada ("Ast...
Themefolio
Profiler
Peergroup
© EQS Newswire
23.04.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Eine neue Ära der Krebsbekämpfung? Dr. James Orbinski kommt ins Advisory Board von Onco-Innovations 
News Preview
EQS-Media / 23.04.2025 / 11:38 CET/CEST Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, gibt die Ernennung von Dr. James Orbinski zum Mitglied des wissenschaftlichen und klinischen Advisory Boards des Unternehmens bekannt. Der ehemalige International President von Médecins Sans Frontières/ Ärzte ohne Grenz......
Themefolio
Profiler
Peergroup
© EQS Newswire
23.04.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Dr. James Orbinski wird Mitglied des wissenschaftlichen und klinischen Advisory Boards von Onco-Innovations, um die Mission des Unternehmens zu fördern
News Preview
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, gibt die Ernennung von Dr. James Orbinski zum Mitglied des wissenschaftlichen und klinischen Advisory Boards des Unternehmens bekannt. Der ehemalige International President von Médecins Sans Frontières/Ärzte ohne Grenzen (MSF) nahm 1999 den Friedensnobelpreis im N......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.04.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Kommt jetzt die zweite Welle? 
News Preview
EQS-Media / 18.04.2025 / 18:35 CET/CEST Onco-Innovations gibt Partnerschaft mit Dalton Pharma zur Isotopensynthese der patentierten PNKP-Technologie bekannt Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), „Onco“ oder das „Unternehmen“ gibt bekannt, dass das Unternehmen im April 2025 eine Vereinbarung mit Dalton Pharma Services über ......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.04.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations meldet Zusammenarbeit mit Dalton Pharma zur Isotopensynthese der patentierten PNKP-Technologie
News Preview
Die PNKP-Technologie verbesserte in früheren Studien die Überlebensrate bei Mäusen mit kolorektalem Karzinom Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass es am 8. April 2025 eine Vereinbarung mit Dalton Pharma Services (Dalton) über die Auftragssynthese eines schwer markiert......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
17.04.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations Announces Partnership with Dalton Pharma for Isotope Synthesis of Patented PNKP Technology
News Preview
PNKP TechnologyShown in Past Study to Increase Survival Rate in Colorectal Cancer Bearing Mice VANCOUVER, BC / ACCESS Newswire / April 17, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company")is pleased to announce that it has entered into an agreement with Dalton Pharma Ser...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
16.04.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations Announces Private Placement
News Preview
Not for distribution to United States wire services or for dissemination in the United States VANCOUVER, BC / ACCESS Newswire / April 16, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN: A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company") announces that it intends to complete a non-brokered private placement (the "...
Themefolio
Profiler
Peergroup
© EQS Newswire
11.04.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Roche-gesponserte Studie von Inka Health, Tochter von Onco-Innovations, veröffentlicht – Förderung der onkologischen Forschung in der Praxis
News Preview
EQS-Media / 11.04.2025 / 10:50 CET/CEST Zeigt die Aktie erneut ein bullisches Momentum? Onco-Innovations-Tochter Inka Health veröffentlicht von Roche-geförderte Studie zur Onkologie Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass seine Tochtergesellschaft Inka Health Corp. ......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.04.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Inka Health, Tochter von Onco-Innovations, veröffentlicht von Roche gesponserte Studie zur Förderung der onkologischen Forschung in der Praxis
News Preview
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass seine Tochtergesellschaft Inka Health Corp. (Inka Health) eine bedeutende und neuartige Studie mit dem Titel Quantitative Bias Analysis for the Assessment of Bias in Comparisons between Synthetic Control Arms (Studie) veröffentlich......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
10.04.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations’ Inka Health Publishes Roche-Sponsored Study Advancing Real-World Oncology Research
News Preview
VANCOUVER, BC / ACCESS Newswire / April 10, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its subsidiary, Inka Health Corp. ("Inka Health"), has published a significant and novel study titled Quantitative Bias Analysis for the A...
Themefolio
Profiler
Peergroup
© EQS Newswire
04.04.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations-Tochter Inka Health erhält Analyseauftrag von AstraZeneca Canada 
News Preview
EQS-Media / 04.04.2025 / 11:20 CET/CEST Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass seine hundertprozentige Tochtergesellschaft Inka Health Corp., eine von AstraZeneca Canada in Auftrag gegebene Analysearbeit (AZ-Dienstleistungsvereinbarung) erfolgreich abgeschlossen ha......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.04.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Mit dem Abschluss des Analyseauftrags für AstraZeneca Canada beschreitet Onco-Innovations-Tochter Inka Health neue Wege in der pharmazeutischen Analytik
News Preview
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass seine hundertprozentige Tochtergesellschaft Inka Health Corp. (Inka Health), die vom Unternehmen am bzw. um den 3. Februar 2025 übernommen wurde (siehe Pressemeldung vom 3. Februar 2025), mittlerweile eine von AstraZeneca Canada (A......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
03.04.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations' Inka Health Completes Analytical Work for AstraZeneca Canada, Advancing Pharmaceutical Analytics and Leading to Key Studies at ISPOR 2025
News Preview
VANCOUVER, BC / ACCESS Newswire / April 3, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly owned subsidiary, Inka Health Corp. ("Inka Health"), which the Company acquired on or about February 3, 2025 (please see news re...
Themefolio
Profiler
Peergroup
© EQS Newswire
27.03.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Steht der nächste Kurssprung bevor? PKNP-Technologie demonstriert in Verbindung mit Strahlentherapie geringe Toxizität und hohes Sicherheitsprofil
News Preview
EQS-Media / 27.03.2025 / 11:42 CET/CEST Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich, Informationen über seine Nanopartikel-Formulierung der zweiten Generation der Polynukleotid-Kinase-3'-Phosphatase-(PNKP)-Verbindung in Kombination mit Strahlentherapie bekannt zu geben, die in einer im Dezemb......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.03.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
PKNP-Technologie von Onco-Innovations in Verbindung mit Strahlentherapie demonstriert in Studie geringe Toxizität und hohes Sicherheitsprofil
News Preview
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich, Informationen über seine Nanopartikel-Formulierung der zweiten Generation der Polynukleotid-Kinase-3'-Phosphatase-(PNKP)-Verbindung (die Technologie) in Kombination mit Strahlentherapie bekannt zu geben, die in einer im Dezember 2021 von Forschern der U......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
26.03.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations' PKNP Technology Used with Radiation Therapy Shown in Study to Demonstrate Low Toxicity and High Safety Profile
News Preview
VANCOUVER, BC / ACCESS Newswire / March 26, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to provide information regarding its second-generation nanoparticle formulation of Polynucleotide Kinase 3'-Phosphatase (PNKP) Compound (the "Technology")...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
25.03.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations Extends Marketing Program
News Preview
VANCOUVER, BC / ACCESS Newswire / March 25, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") announces that it has extended the term of its engagement with MCS Market Communication Service GmbH (business address: Rheinpromenade 13, 40789 Monheim am Rhein, Nordrhein-West...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
24.03.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations Provides Update on Use of Proceeds
News Preview
VANCOUVER, BC / ACCESS Newswire / March 24, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H), (WKN: A3EKSZ ) (" Onco " or the " Company "), at the request of the Canadian Securities Exchange, provides, by way of the table below, an update to the use of proceeds disclosure contained in its prospectus dated N...
Themefolio
Profiler
Peergroup
© EQS Newswire
06.03.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Steiler Expansionskurs wird fortgesetzt - exklusives Interview mit Onco-CEO, Thomas O'Shaughnessy
News Preview
EQS-Media / 06.03.2025 / 12:41 CET/CEST Onco Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ) revolutioniert als Pionier der kanadischen Bio-Tech-Branche die Krebsforschung mit bahnbrechenden Technologien. Das Unternehmen hat sich die weltweite Exklusivlizenz für eine patentierte Technologie gesichert, die gezielt solide Tumore bekämpft und......
Themefolio
Profiler
Peergroup
© EQS Newswire
03.03.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations-CEO über KI und globale Wachstumspläne
News Preview
EQS-Media / 03.03.2025 / 11:03 CET/CEST Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass CEO Thomas OShaughnessy vor Kurzem in einem exklusiven Interview bei “Conversations That Matter”, einer beliebten Sendung, in der Vordenker vorgestellt werden, die die Welt gestalten, au......
Themefolio
Profiler
Peergroup
© EQS Newswire
03.03.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Thomas OShaughnessy, CEO von Onco-Innovations, spricht bei “Conversations That Matter” über bahnbrechende Entwicklungen in der Krebsbehandlung, KI-Integration und eine mögliche globale Expansion
News Preview
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass CEO Thomas OShaughnessy vor Kurzem in einem exklusiven Interview bei “Conversations That Matter”, einer beliebten Sendung, in der Vordenker vorgestellt werden, die die Welt gestalten, auftrat. Die Sendung wurde in der “Vancouver Su......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
02.03.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations CEO Thomas O’Shaughnessy Featured on Conversations That Matter to Discuss Breakthroughs in Cancer Treatment, AI Integration, and Potential Global Expansion
News Preview
VANCOUVER, BC / ACCESS Newswire / March 2, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt: W1H)(WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that its CEO, Thomas O'Shaughnessy, was recently featured in an exclusive interview on Conversations That Matter, a widely distributed long-form program s...
Themefolio
Profiler
Peergroup
© EQS Newswire
28.02.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Innovative KI-gesteuerte Studie von Inka Health ebnet den Weg für neue Forschung
News Preview
EQS-Media / 28.02.2025 / 10:55 CET/CEST Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich, Informationen über seine hundertprozentige Tochtergesellschaft Inka Health (Inka) bereitzustellen, die durch die Durchführung eines im September 2024 in medRxiv veröffentlichten transformativen Studienprüfpla......
Themefolio
Profiler
Peergroup
© EQS Newswire
28.02.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Innovative KI-gesteuerte Onkologiestudie von Inka Health, Tochter von Onco-Innovations, ebnet den Weg für neue Forschung
News Preview
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich, Informationen über seine hundertprozentige Tochtergesellschaft Inka Health (Inka) bereitzustellen, die durch die Durchführung eines im September 2024 in medRxiv veröffentlichten transformativen Studienprüfplans, External Control Arm with Synthetic Real-......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
27.02.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations' Inka Health Innovative AI-Driven Oncology Study Paves the Way for New Research
News Preview
VANCOUVER, BC / ACCESS Newswire / February 27, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to provide information regarding its wholly-owned subsidiary, Inka Health ("Inka"), which has made significant strides in advancing AI-driven oncology re...
Themefolio
Profiler
Peergroup
© EQS Newswire
25.02.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Studie belegt geringe Toxizität bei hohem Sicherheitsprofil
News Preview
EQS-Media / 25.02.2025 / 10:57 CET/CEST Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich Informationen zu seiner Nanopartikel-Formulierung der zweiten Generation des Polynukleotid-Kinase-3-Phosphatase-(PNKP)-Wirkstoffs bekannt zu geben, insbesondere, dass sie in einer im Juni 2021 von Forschern de......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.02.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
PKNP-Technologie von Onco-Innovations zeigte in Studie geringe Toxizität bei hohem Sicherheitsprofil
News Preview
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ) (Onco oder das Unternehmen) freut sich Informationen zu seiner Nanopartikel-Formulierung der zweiten Generation des Polynukleotid-Kinase-3-Phosphatase-(PNKP)-Wirkstoffs (die Technologie) bekannt zu geben, insbesondere, dass sie in einer im Juni 2021 von Forschern der University of Alberta, Ka......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
24.02.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations' PKNP Technology Shown in Study to Demonstrate Low Toxicity and High Safety Profile
News Preview
VANCOUVER, BC / ACCESS Newswire / February 24, 2025 / Onco-Innovations Limited(CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to provide information regarding its second-generation nanoparticle formulation of Polynucleotide Kinase 3'-Phosphatase (PNKP) Compound (the "Technology"),...
Themefolio
Profiler
Peergroup
© EQS Newswire
22.02.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Vielversprechender Wachstumsimpuls? Onco-Tochter Inka Health meldet provisorische USPTO-Patentanmeldung für SynoGraph
News Preview
EQS-Media / 22.02.2025 / 13:05 CET/CEST Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass seine hundertprozentige Tochtergesellschaft Inka Health (Inka) eine provisorische Patentanmeldung beim United States Patent and Trademark Office (USPTO) für seine KI-Plattform der nächst......
Themefolio
Profiler
Peergroup
© EQS Newswire
22.02.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations informiert über provisorische USPTO-Patentanmeldung für SynoGraph, die KI-gestützte Plattform für Präzisionsmedizin, durch Inka Health
News Preview
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass seine hundertprozentige Tochtergesellschaft Inka Health (Inka) eine provisorische Patentanmeldung beim United States Patent and Trademark Office (USPTO) für seine KI-Plattform der nächsten Generation, SynoGraph, eingereicht hat. Di......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
21.02.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations Provides Information Regarding Inka Health's USPTO Provisional Patent Application for AI-Powered Precision Medicine Platform, SynoGraph
News Preview
VANCOUVER, BC / ACCESS Newswire / February 21, 2025 / Onco-Innovations Limited(CSE:ONCO)(OTCQB:ONNVF) (Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly owned subsidiary, Inka Health ("Inka"), filed a provisional patent application with the United States Patent and Trademark Of...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
21.02.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations Announces U.S. Listing on the OTCQB Market
News Preview
VANCOUVER, BC / ACCESS Newswire / February 21, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt: W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its common shares have commenced trading on the OTCQB marketplace under the symbol "ONNVF". The Company's shares will continue to trade...
Themefolio
Profiler
Peergroup
© EQS Newswire
15.02.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations PNKP-Hemmer zeigt starke Wirkung 
News Preview
EQS-Media / 15.02.2025 / 11:41 CET/CEST Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich, Informationen über seine lizenzierte Nanopartikel-Formulierung einer neuen Klasse von Polynukleotidkinase-3'-Phosphatase (PNKP)-Hemmern (die Technologie oder der PNKP-Wirkstoff) bereitzustellen, die sich bei ......
Themefolio
Profiler
Peergroup
© EQS Newswire
15.02.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
PNKP-Inhibitoren in Nanopartikel-Formulierung von Onco-Innovations in Kombination mit Strahlentherapie und als alleinstehende Behandlung verlangsamen in Studien das Wachstum von Darmkrebs-Tumoren
News Preview
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich, Informationen über seine lizenzierte Nanopartikel-Formulierung einer neuen Klasse von Polynukleotidkinase-3'-Phosphatase (PNKP)-Hemmern (die Technologie oder der PNKP-Wirkstoff) bereitzustellen, die sich bei der Verlangsamung des Wachstums von Darmkrebs......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
14.02.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Onco-Innovations' Nanoparticle Formulation PNKP Technology Combined with Radiation Therapy, and as a Standalone Treatment, Shown in Studies to Slow Colorectal Cancer Tumour Growth
News Preview
VANCOUVER, BC / ACCESS Newswire / February 14, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to provide information on its licensed nanoparticle formulation of a new class of Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitors (the "Technology" or "PN...
Themefolio
Profiler
Peergroup
© EQS Newswire
11.02.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

NEO
Neue Technologie im Kampf gegen Krebs erhöht in einer Tierstudie die Empfindlichkeit von Krebszellen gegenüber Strahlung
News Preview
EQS-Media / 11.02.2025 / 10:40 CET/CEST Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich, Informationen über seine exklusiv lizenzierte Technologie, eine neue Klasse von Polynukleotidkinase-3-Phosphatase (PNKP)-Hemmern, die vielversprechende Ergebnisse bei der Verbesserung der Empfindlichkeit von ......
Themefolio
Profiler
Peergroup

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

© 2025 Select Sector SPDRs

* * *

More Sector related Investment Ideas
© 2025 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Monday, 01.12.2025, Calendar Week 49, 335th day of the year, 30 days remaining until EoY.